Primary insomnia
Conditions
Interventions
Remazolam low dose group:2mg right Zopiclone was given on the night before surgery and a smart bracelet was worn. General anesthesia was induced by low dose remazolam 0.15mg/kg on the day of surgery.
Control group:No treatment was done on the night before surgery
General anesthesia was induced by propofol 2.5mg/kg on the day of operation
Remazolam medium dose group:2mg right Zopicron was given on the night before surgery and a smart bracelet was worn. General anesthesia was induced by medium dose remazolam 0.25mg/kg on the
Remazolam high dose group:On the night before surgery, 2mg dexzopicron was given and smart bracelet was worn. On the day of surgery, general anesthesia was induced by high dose remazolam 0.35mg/kg.
Sponsors
Ordos Central Hospital
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with delirium according to the Diagnostic and Statistical Manual of Mental Disorders (4th Edition) (DSM-IV). This included insomnia as the main issue, which comprised difficulty falling asleep, lack of deep sleep, frequent dreams, early awakenings, or problems falling asleep after waking, as well as tiredness or daytime sleepiness; 2) The primary concern was that frustration with the sleep quality leads to considerable distress or hinders social functioning; More than 3 nights/week for at least 1 month; 3) Age >= 65 years old; 4) The informed consent was signed by the patient, who willingly participated in the study.
Exclusion criteria
Exclusion criteria: 1) Recent use of medications that affect cognitive function (e.g., benzodiazepines, antidepressants/anxiety drugs, antiepileptic drugs) and a history of abuse substances; 2) Other conditions that may affect cognitive function (e.g. brain injury, stroke, mental illness, sleep apnea syndrome, chronic obstructive emphysema, hypothyroidism, hyperthyroidism, AIDS, kidney failure, Parkinson, Alzheimer, severe liver diseases, and, blood diseases); 3) The patients who withdrew, those who did not consent to be selected, and those with clear visual and auditory impairments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| S100ß;Orexin A;Cognitive function;Sleep quality;Sedation and analgesia; | — |
Countries
China
Contacts
Public ContactShujuan Wang
Ordos Central Hospital
Outcome results
None listed